Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Mohamad Mohty and Annalisa Ruggeri.
Connection Strength

2.506
  1. Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2021 03; 56(3):532-535.
    View in: PubMed
    Score: 0.222
  2. Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT. Bone Marrow Transplant. 2019 12; 54(12):1987-1994.
    View in: PubMed
    Score: 0.206
  3. Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria. Haematologica. 2019 08; 104(8):1682-1688.
    View in: PubMed
    Score: 0.202
  4. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. J Hematol Oncol. 2018 03 15; 11(1):40.
    View in: PubMed
    Score: 0.190
  5. Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study. Biol Blood Marrow Transplant. 2018 07; 24(7):1471-1475.
    View in: PubMed
    Score: 0.189
  6. Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. Cancer. 2018 04 01; 124(7):1428-1437.
    View in: PubMed
    Score: 0.188
  7. Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors. Biol Blood Marrow Transplant. 2018 05; 24(5):1013-1021.
    View in: PubMed
    Score: 0.187
  8. Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT. Oncotarget. 2017 Dec 22; 8(68):112972-112979.
    View in: PubMed
    Score: 0.186
  9. The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. Blood Adv. 2017 Apr 25; 1(11):669-680.
    View in: PubMed
    Score: 0.178
  10. Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation. Eur J Haematol. 2019 Jul; 103(1):10-17.
    View in: PubMed
    Score: 0.051
  11. Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT. Bone Marrow Transplant. 2019 09; 54(9):1499-1510.
    View in: PubMed
    Score: 0.050
  12. Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. Am J Hematol. 2018 10; 93(10):1236-1244.
    View in: PubMed
    Score: 0.049
  13. Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2019 04; 54(4):519-530.
    View in: PubMed
    Score: 0.049
  14. Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study. Blood. 2018 08 16; 132(7):750-754.
    View in: PubMed
    Score: 0.048
  15. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol. 2018 04 16; 11(1):55.
    View in: PubMed
    Score: 0.048
  16. Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia. Bone Marrow Transplant. 2018 10; 53(10):1295-1303.
    View in: PubMed
    Score: 0.048
  17. Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. Am J Hematol. 2018 06; 93(6):769-777.
    View in: PubMed
    Score: 0.048
  18. Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen. Clin Cancer Res. 2018 06 15; 24(12):2794-2803.
    View in: PubMed
    Score: 0.047
  19. T-cell-depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT). Cancer. 2018 05 15; 124(10):2142-2150.
    View in: PubMed
    Score: 0.047
  20. Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers. Haematologica. 2018 03; 103(3):e103-e105.
    View in: PubMed
    Score: 0.047
  21. Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017 11; 102(11):1810-1822.
    View in: PubMed
    Score: 0.046
  22. An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. Clin Cancer Res. 2017 Nov 01; 23(21):6478-6486.
    View in: PubMed
    Score: 0.045
  23. Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. J Hematol Oncol. 2017 06 21; 10(1):128.
    View in: PubMed
    Score: 0.045
  24. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. Cancer. 2017 Aug 01; 123(15):2867-2874.
    View in: PubMed
    Score: 0.044
  25. Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. Blood Adv. 2017 Feb 28; 1(7):477-485.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.